People with Huntington’s disease who have a greater sense of purpose and meaning are more likely to find contentment in life and have better health-related quality of life, regardless of the severity of most of their symptoms. That’s according to the study “Meaning and purpose in…
A motion to expand specialist services for families in Scotland affected by Huntington’s disease (HD) received what’s being hailed as a historic level of cross-party support in the Scottish Parliament. Backed by 98% of members of the Scottish Parliament (MSPs), the call to action is said to be the…
Certain people with Huntington’s disease — specifically, younger adults with milder disease — may have benefited from treatment with tominersen in the Phase 3 GENERATION HD1 clinical trial, according to a new analysis of study data. Based on the results, its developer Roche is planning to launch a Phase 2…
Annexon’s investigational therapy ANX005 is showing tolerability and a potential to treat people in the earlier stages of Huntington’s disease or at genetic risk of the disorder, according to interim data from an ongoing Phase 2 trial. ANX005, an antibody designed to inhibit the activation of the complement cascade —…
People with Huntington’s disease are more likely to take Austedo (deutetrabenazine) as directed, compared with the similar medication Xenazine (tetrabenazine), according to a new study. The study also found lower discontinuation rates with Austedo, which may suggest that, between these two treatments for chorea, Austedo tends to…
Throughout 2021, Huntington’s Disease News brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to Huntington’s disease. As a reminder of what mattered most to you last year, here are the top 10 most-read articles of 2021 with a brief description of what made…
The experimental oral medication branaplam (LMI070) has been granted fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for Huntington’s disease, according to an announcement from the therapy’s developer, Novartis. This designation is designed to speed the development and review of…
AMT-130, an investigational gene therapy for the treatment of Huntington’s disease, was overall well-tolerated up to a year after treatment in the first patients to receive the therapy in a clinical trial. The new data, announced by AMT-130’s developer uniQure, cover the first four participants in a Phase…
Treatment with valbenazine significantly lessened chorea — a motor symptom characterized by jerky, unpredictable, and involuntary movements — in people with Huntington’s disease in the Phase 3 clinical trial KINECT-HD, according to an announcement from the therapy’s developer, Neurocrine Biosciences. Neurocrine now is planning to submit an…
The Huntington Study Group is seeking 30 patients to join KINECT-HD2, an open-label study of oral valbenazine capsules for chorea, or jerky involuntary movements, in Huntington’s disease, a press release states. KINECT-HD2 is an extension study of KINECT-HD (NCT04102579), a Phase 3 clinical trial that tested…
Get regular updates to your inbox.